TherapeuticsMD, Inc. (TXMD) Q2 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

for the Therapeutics MD Second Quarter 2022 Financial Results Conference Call. Following prepared remarks from the company, we will open the call for questions. I would now like to turn the call over to Investor Relations for Therapeutics MD, Lisa Wilson. Lisa? Thank you, Operator. Good morning, everyone, and thank you for joining today to discuss our second quarter financial results and business updates. This morning, TherapeuticsMD issued a press release announcing its second quarter 2022 financial results. The press release and accompanying presentation are available on the company's website, TherapeuticsMD, in the Investors and Media section. On today's call from TherapeuticsMD are Chief Executive Officer Hugh O'Dowd, Interim Chief Financial Officer Michael Donegan, and Chief Commercial Officer Mark Glickman. I would like to remind everyone that certain statements made during this conference call may be forward-looking statements. Such forward-looking statements are based upon current expectations and there can be no assurance that the results contemplated in these statements will be realized. Actual results may differ materially from such statements due to a number of factors and risks, some of which are identified in our press release and our annual, quarterly, and other reports filed with the SEC. These forward-looking statements are based on information available to TherapeuticsMD as of today, and the company assumes no obligation to update these statements as circumstances change. An audio recording and webcast replay for today's conference call will also be available online in the Investors and Media section of the company's website. For the benefit of those who may be listening to the replay or archived webcast, this call was held and recorded on August 15...